News & Updates

Treatment with zuranolone 50 mg/day in adults with major depressive disorder (MDD) results in greater improvements in depressive symptoms at day 15, demonstrating a rapid time to effect (day 3), and is generally well tolerated, with no new safety concerns compared with lower dosages, reports a study.

Local intranasal treatment with budesonide does not appear to be effective for persistent hyposmia in patients with nonsevere COVID-19, according to a study.

Use of zuranolone significantly improves depressive symptoms, with no serious side effects, in women with severe postpartum depression (PPD), a common perinatal complication with adverse maternal and infant outcomes, results of a phase III trial have shown.

Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) appears to increase the risk of venous thromboembolism (VTE) in women using hormonal contraception, reveals a study.

In cancer patients with isolated distal deep vein thrombosis (IDDVT), a 12-month anticoagulation regimen with the oral factor Xa inhibitor edoxaban fared better than a 3-month regimen, findings from the ONCO DVT study have shown.

Colorectal cancer screening should wait until age 50 for average-risk, asymptomatic adults, says the American College of Physicians (ACP) in its updated guidance. However, this stands in contrast to screening recommendations by the American Cancer Society (ACS) and the US Preventive Services Task Force (USPSTF) to start at age 45.